Cure My Disease

Don't miss your cure!

 Log in / Sign up

New heart drug aficamten shows promise for japanese patients with thick heart muscle

NCT ID NCT07023341

Ongoing Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial is testing a drug called aficamten in 36 Japanese adults with symptomatic obstructive hypertrophic cardiomyopathy, a condition where the heart muscle thickens and makes it hard to pump blood. The drug aims to reduce over-contraction of the heart muscle. Researchers will measure changes in heart blood flow and quality of life after 6 months of treatment, and participants can continue the drug long-term if it helps.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

aficamten (also called BAY3723113)

What this could lead to

If successful, aficamten could offer a new treatment option for Japanese people with symptomatic obstructive hypertrophic cardiomyopathy, targeting the root cause of the disease.

What could go wrong

This is a single-arm, open-label study with only 36 participants, so results may not apply broadly. Long-term safety and effectiveness are still being evaluated.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

Contacts and locations

Locations

  • Hamamatsu University Hospital

    Hamamatsu, Shizuoka, 431-3192, Japan

  • Hyogo Prefectural HarimaHimeji General Medical Center

    Himeji, Hyōgo, 670-8560, Japan

  • Iwate Prefectural Central Hospital

    Morioka, Iwate, 020-0066, Japan

  • Kitasato University Hospital

    Sagamihara, Kanagawa, 252-0375, Japan

  • Kobe City Medical Center General Hospital

    Kobe, Hyōgo, 650-0047, Japan

  • Kochi Medical School Hospital

    Nankoku, Kochi, 783-8505, Japan

  • Kumamoto University Hospital

    Kumamoto, 860-8556, Japan

  • Kurashiki Central Hospital

    Kurashiki, Okayama-ken, 710-8602, Japan

  • Kurume University Hospital

    Kurume, Fukuoka, 830-0011, Japan

  • Matsushita Memorial Hospital

    Moriguchi, Osaka, 570-8540, Japan

  • Mie University Hospital

    Tsu, Mie-ken, 514-8507, Japan

  • National Cerebral and Cardiovascular Center

    Suita, Osaka, 564-8565, Japan

  • Nippon Medical School Hospital

    Bunkyo-ku, Tokyo, 113-8602, Japan

  • SHOWA Medical University Fujigaoka Hospital

    Yokohama, Kanagawa, 227-8501, Japan

  • Saiseikai Fukuoka General Hospital

    Fukuoka, 810-0001, Japan

  • Saiseikai Kumamoto Hospital

    Kumamoto, 861-4193, Japan

  • Sakakibara Heart Institute

    Fuchū, Tokyo, 183-0003, Japan

  • Showa Medical University Koto Toyosu Hospital

    Koto-ku, Tokyo, 135-8577, Japan

  • The University of Osaka Hospital

    Suita, Osaka, 565-0871, Japan

  • The University of Tokyo Hospital

    Bunkyo, Tokyo, 113-8655, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, 980-8574, Japan

  • University Hospital, Kyoto Prefectural University of Medicine

    Kyoto, 602-8566, Japan

  • University of Tsukuba Hospital

    Tsukuba, Ibaraki, 305-8576, Japan

  • University of the Ryukyus Hospital

    Ginowan, Okinawa, 901-2725, Japan